Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

Chi-Ling Chiang, Frank W Frissora, Zhiliang Xie, Xiaomeng Huang, Rajeswaran Mani, DVM, Sivasubramanian Baskar, Christoph Rader, Kenneth K. Chan, Guido Marcucci, MD, John C. Byrd, MD, L. James Lee, Natarajan Muthusamy, DVM, PhD

Blood (2015) 126 (23): 1743.

https://doi.org/10.1182/blood.V126.23.1743.1743

Published: 2015

Journal Articles

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Hongyan Wang, PhD, Ramasamy Santhanam, Ph.D, Zhiliang Xie, MD, Xiaomeng Huang, Ming Chiu, Mitch A. Phelps, PhD, Alison R Walker, MD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, James Lee, PhD, Natarajan Muthusamy, DVM, Ph.D, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2013) 122 (21): 3933.

https://doi.org/10.1182/blood.V122.21.3933.3933

Published: 2013

Journal Articles

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia

Bo Yu, Yicheng Mao, Li-Yuan Bai, Sarah E. M. Herman, Xinmei Wang, Asha Ramanunni, Yan Jin, Xiaokui Mo, Carolyn Cheney, Kenneth K. Chan, David Jarjoura, Guido Marcucci, Robert J. Lee, John C. Byrd, L. James Lee, Natarajan Muthusamy

Blood (2013) 121 (1): 136–147.

https://doi.org/10.1182/blood-2012-01-407742

Published: 2013

Includes: Supplemental data

Journal Articles

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Blood (2012) 120 (21): 2422.

https://doi.org/10.1182/blood.V120.21.2422.2422

Published: 2012

Journal Articles

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Hongyan Wang, Ping Chen, Ph.D., Jiang Wang, Ramasamy Santhanam, Ph.D, Josephine Aimiuwu, Vijayasaradhi UV, Zhongfa Liu, Sebastian Schwind, MD, Alice S. Mims, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Michael R. Grever, MD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Ramiro Garzon, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3578.

https://doi.org/10.1182/blood.V120.21.3578.3578

Published: 2012

Journal Articles

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Rebecca B Klisovic, MD, Hongyan Wang, Alison Walker, MD, Katherine Walsh, MD, Sumithira Vasu, MBBS, Ramiro Garzon, MD, Steven M. Devine, MD, Jiang Wang, Celia Garr, RN, Adam Norris, John C. Byrd, MD, Michael R. Grever, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3616.

https://doi.org/10.1182/blood.V120.21.3616.3616

Published: 2012

Journal Articles

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

Blood (2012) 119 (25): 6025–6031.

https://doi.org/10.1182/blood-2012-03-413898

Published: 2012

Includes: Supplemental data

Journal Articles

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Josephine Aimiuwu, Hongyan Wang, Ping Chen, Zhiliang Xie, Jiang Wang, Shujun Liu, Rebecca Klisovic, Alice Mims, William Blum, Guido Marcucci, Kenneth K. Chan

Blood (2012) 119 (22): 5229–5238.

https://doi.org/10.1182/blood-2011-11-382226

Published: 2012

Includes: Supplemental data

Journal Articles

Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine

Donald Lavelle, Kestis Vaitkus, Yonghua Ling, Maria A. Ruiz, Reda Mahfouz, Kwok Peng Ng, Soledad Negrotto, Nicola Smith, Pramod Terse, Kory J. Engelke, Joseph Covey, Kenneth K. Chan, Joseph DeSimone, Yogen Saunthararajah

Blood (2012) 119 (5): 1240–1247.

https://doi.org/10.1182/blood-2011-08-371690

Published: 2012

Includes: Supplemental data

Journal Articles

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Xiaomeng Huang, Sebastian Schwind, MD, Bo Yu, Ph.D, Jiuxia Pang, Ramasamy Santhanam, Ph.D, Kenneth K. Chan, Ph.D, Ramiro Garzon, MD, William Blum, MD, Clara D. Bloomfield, MD, Shujun Liu, Ph.D, Danilo Perrotti, MD, Ph.D, Robert J. Lee, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, L. James Lee, Ph.D, Guido Marcucci, MD

Blood (2011) 118 (21): 81.

https://doi.org/10.1182/blood.V118.21.81.81

Published: 2011

Journal Articles

Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes

Reda Z Mahfouz, MD, Ania Jankowska, PhD, Quteba Ebrahem, MD, Zhenbo Hu, MD, Kenneth K. Chan, Ph.D, Donald Lavelle, Ph.D., Joseph DeSimone, PhD, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD, BS, Jaroslaw P. Maciejewski, MD, PhD, Yogen Saunthararajah, M.D.

Blood (2011) 118 (21): 1434.

https://doi.org/10.1182/blood.V118.21.1434.1434

Published: 2011

Journal Articles

Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia.

Bo Yu, Yicheng Mao, Li-Yuan Bai, Sarah E.M. Herman, Asha Ramanunni, Yan Jin, Xiaokui Mo, PhD, Carolyn Cheney, Kenneth K. Chan, PhD, David Jarjoura, Guido Marcucci, MD, Robert Lee, L.James Lee, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2010) 116 (21): 1475.

https://doi.org/10.1182/blood.V116.21.1475.1475

Published: 2010

Journal Articles

The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia

Nicholas Zorko, Susan P. Whitman, PhD, Kelsie Bernot, PhD, Myntee T. Ngangana, Ronald Siebenaler, Shujun Liu, Ph.D., Yue-Zhong Wu, MS, Chidimma Kalu, Xiaoli Zhang, PhD, MS, David Jarjoura, PhD, Zhiliang Xie, MD, Kenneth K. Chan, PhD, Adrienne M. Dorrance, PhD, Benjamin H. Lee, MD, PhD, Roger Briesewitz, PhD, Danilo Perrotti, MD, PhD, Guido Marcucci, MD, Michael A. Caligiuri, MD

Blood (2010) 116 (21): 150.

https://doi.org/10.1182/blood.V116.21.150.150

Published: 2010

Journal Articles

Tetrahydrouridine Co-Administration Improves Oral Bioavailability and Dampens Inter-Individual Variability of Decitabine Pharmacokinetics In Baboons

Donald Lavelle, Ph.D., Kestis Vaitkus, YongHua Ling, Nicola Smith, Kenneth K. Chan, PhD, Joseph DeSimone, PhD, Yogenthiran Saunthararajah, MD

Blood (2010) 116 (21): 2081.

https://doi.org/10.1182/blood.V116.21.2081.2081

Published: 2010

Journal Articles

Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.

Shujun Liu, PhD, Lai Chu Wu, PhD, Jiuxia Pang, BS, Ramasamy Santhanam, PhD, Sebastian Schwind, MD, Yue-Zhong Wu, MS, Christopher Hickey, MS, Jianhua Yu, PhD, Anjali Mishra, PhD, Heiko Becker, MD, Chenglong Li, PhD, Roger Briesewitz, PhD, Robert A. Baiocchi, MD, Kenneth K. Chan, PhD, Michael A. Caligiuri, MD, John C. Byrd, MD, Danilo Perrotti, MD, PhD, Ramiro Garzon, MD, Guido Marcucci, MD

Blood (2009) 114 (22): 938.

https://doi.org/10.1182/blood.V114.22.938.938

Published: 2009

Journal Articles

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Ping Chen, Ph.D., William Blum, M.D., Josephine Aimiuwu, B.S., Vijayasarathi Upadhyayula, Ph.D., Zhongfa Liu, Ph.D., Shujun Liu, Ph.D., Jiuxia Pang, B.S., Alison Walker, M.D., Rebecca B. Klisovic, M.D., Ramiro Garzon, M.D., Michael R. Grever, M.D., Miguel Villalona-Calero, M.D., John C. Byrd, M.D., Kenneth K Chan, Ph.D., Guido Marcucci, M.D.

Blood (2009) 114 (22): 3782.

https://doi.org/10.1182/blood.V114.22.3782.3782

Published: 2009

Journal Articles

A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation

Kristie A. Blum, MD, Zhongfa Liu, David M. Lucas, Robert Baiocchi, Thomas S. Lin, Don Benson, Steven M. Devine, Jeffrey Jones, Leslie Andritsos, Joseph Flynn, Ping Cheng, Zhiliang Xie, Guido Marcucci, Kenneth K. Chan, Michael R. Grever, John C. Byrd

Blood (2008) 112 (11): 3169.

https://doi.org/10.1182/blood.V112.11.3169.3169

Published: 2008

Journal Articles

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca Klisovic, MD, Shujun Liu, PhD, Ramiro Garzon, MD, Cheryl Kefauver, RN, Zhongfa Liu, PhD, Jon Mickle, CNP, Hollie Devine, CNP, Steve Devine, MD, Michael R Grever, MD, Kenneth K Chan, PhD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Guido Marcucci, MD

Blood (2008) 112 (11): 2957.

https://doi.org/10.1182/blood.V112.11.2957.2957

Published: 2008

Journal Articles

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB–dependent DNA methyltransferase activity in acute myeloid leukemia

Blood (2008) 111 (4): 2364–2373.

https://doi.org/10.1182/blood-2007-08-110171

Published: 2008

Journal Articles

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Blanche Mavromatis, MD, Kanti R. Rai, MD, Paul K. Wallace, PhD, Claudia Soho, OCN, Beverly Landrigan, RN, Patricia Meyn, RN, Tracey Wei, MS, Kenneth K. Chan, PhD, Philomena Casey, MS, Steven C. Novick, MD, PhD, Asher A. Chanan-Khan, MD

Blood (2005) 106 (11): 2129.

https://doi.org/10.1182/blood.V106.11.2129.2129

Published: 2005

NARROW

Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes

Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia.

The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia

Tetrahydrouridine Co-Administration Improves Oral Bioavailability and Dampens Inter-Individual Variability of Decitabine Pharmacokinetics In Baboons

Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB–dependent DNA methyltransferase activity in acute myeloid leukemia

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only